The FDA on March 22, 2021 approved KEYTRUDA® in combination with Platinum and Fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced Esophageal or Gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the GastroEsophageal Junction) carcinoma, who are not candidates for surgical resection or definitive chemoradiation. KEYTRUDA® is a product of Merck Sharp & Dohme Corp.
Bottom Ad
Advertisement
Subscribe
